BioSpace News Archive

Nordic Nanovector ASA announces that Ms. Malene Brondberg has been appointed interim Chief Executive Officer with immediate effect.

XNK Therapeutics AB announced that the first patient has been included in a Phase II clinical study to treat patients with Multiple myeloma using XNK’s leading autologous natural killer cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa.

Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA based therapeutics for patients with cardiac diseases, announced the appointment of Rahul Agrawal, MD, as Chief Medical Officer.

Oyster Point Pharma, Inc., announced preclinical data in non-human primates and in vitro models evaluating OC-01 nasal spray against SARS-CoV-2 and the alpha and beta variants, the viruses that cause COVID-19 disease.

HUTCHMED Limited announces that the U.S. Food and Drug Administration has accepted its filing of the New Drug Application for surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumors.

Ault Global Holdings, Inc. a diversified holding company, announced that Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, submitted an investigational new drug application to the FDA for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021.

Pharvaris announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology Annual Congress 2021, to be held virtually July 10-16, 2021.

Concert Pharmaceuticals, Inc. will present an update from its ongoing open label, long-term extension study of the investigational medicine CTP-543 in patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss.

EQRx, a company committed to developing and delivering important new medicines to patients at radically lower prices, announced the appointment of Carlos Garcia-Echeverria, Ph.D., as chief of Rx creation.

HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced the U.S. Food and Drug Administration has reviewed the company’s Investigational New Drug Application and provided a notice to proceed for a U.S.-based Phase 1 clinical trial of its HDT-301 COVID-19 RNA vaccine.